Assembly Biosciences (ASMB) Accumulated Expenses (2011 - 2021)

Assembly Biosciences' Accumulated Expenses history runs 11 years deep, the most recent figure standing at $3.7 million for Q3 2021.

• On a quarterly basis, Accumulated Expenses fell 15.88% year-over-year to $3.7 million in Q3 2021; TTM through Sep 2021 was $3.7 million, a 15.88% decrease from a year earlier, with the FY2020 full-year figure at $4.4 million, down 16.34% from the prior year.
• Accumulated Expenses improved to $3.7 million in Q3 2021 per ASMB's latest filing, from $3.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $10.1 million in Q1 2019 and bottomed at $2.8 million in Q2 2019.
• The 5-year median for Accumulated Expenses is $4.5 million (2020), against an average of $5.2 million.
• Across the five-year window, Accumulated Expenses jumped 222.84% in 2017 and tumbled 54.31% in 2020, its largest moves.
• Year by year, Accumulated Expenses stood at $6.4 million in 2017, then decreased by 26.84% to $4.6 million in 2018, then grew by 14.3% to $5.3 million in 2019, then retreated by 16.34% to $4.4 million in 2020, then retreated by 15.75% to $3.7 million in 2021.
• Per Business Quant, the three latest ASMB Accumulated Expenses figures stand at $3.7 million (Q3 2021), $3.7 million (Q2 2021), and $4.3 million (Q1 2021).